Sunshine Biopharma, Inc. is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company�s lead compound, Adva-27a is a multi-purpose anti-tumor. Its drug candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer. As of December 31, 2011, the Company planned to conduct its Phase I clinical trials for Adva-27a. In July 2014, the Company formed Sunshine Biopharma Canada Inc.